JO
ABCL icon

John Overdeck’s AbCellera Biologics ABCL Stock Holding History

John Overdeck’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.9M Sell
10,437,431
-124,634
-1% -$609K 0.06% 369
2026
Q1 		$36.9M Buy
10,562,065
+4,751,080
+82% +$17.1M 0.03% 631
2025
Q4 		$19.9M Buy
5,810,985
+635,843
+12% +$2.84M 0.03% 726
2025
Q3 		$26M Buy
5,175,142
+1,064,290
+26% +$4.69M 0.04% 537
2025
Q2 		$14.1M Buy
4,110,852
+984,063
+31% +$2.45M 0.03% 674
2025
Q1 		$6.97M Sell
3,126,789
-130,522
-4% -$374K 0.01% 950
2024
Q4 		$9.54M Buy
3,257,311
+723,676
+29% +$2.02M 0.02% 770
2024
Q3 		$6.59M Buy
2,533,635
+472,279
+23% +$1.31M 0.01% 946
2024
Q2 		$6.1M Buy
2,061,356
+580,441
+39% +$2.2M 0.01% 922
2024
Q1 		$6.71M Buy
1,480,915
+411,677
+39% +$2.1M 0.02% 821
2023
Q4 		$6.11M Sell
1,069,238
-128,234
-11% -$594K 0.01% 882
2023
Q3 		$5.51M Buy
1,197,472
+134,292
+13% +$817K 0.01% 849
2023
Q2 		$6.87M Buy
1,063,180
+300,834
+39% +$2.05M 0.02% 798
2023
Q1 		$5.75M Sell
762,346
-198,366
-21% -$1.8M 0.02% 840
2022
Q4 		$9.73M Sell
960,712
-239,826
-20% -$2.77M 0.03% 568
2022
Q3 		$11.9M Buy
1,200,538
+472,616
+65% +$5.19M 0.04% 439
2022
Q2 		$7.75M Buy
727,922
+231,938
+47% +$1.96M 0.03% 598
2022
Q1 		$4.84M Sell
495,984
-19,616
-4% -$186K 0.01% 946
2021
Q4 		$7.37M Buy
515,600
+431,500
+513% +$6.55M 0.02% 967
2021
Q3 		$1.69M Sell
84,100
-293,116
-78% -$5.18M ﹤0.01% 2146
2021
Q2 		$8.3M Buy
377,216
+265,931
+239% +$7.33M 0.02% 912
2021
Q1 		$3.78M Buy
+111,285
New +$4.43M 0.01% 1244

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

John Overdeck's ABCL Position: Q2 2026 in Review

John Overdeck reduced its AbCellera Biologics (ABCL) stake by 1.2% in Q2 2026, selling an estimated $609K and leaving 10,437,431 shares worth $81.9M. The position accounts for 0.06% of the portfolio, ranked #369.

John Overdeck first reported a position in ABCL in Q1 2021 and has held it in 22 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • John Overdeck held 10,437,431 shares of AbCellera Biologics worth $81.9M as of Q2 2026.
  • John Overdeck sold 124,634 AbCellera Biologics shares in Q2 2026, an estimated $609K.
  • AbCellera Biologics made up 0.06% of John Overdeck's portfolio in Q2 2026, its #369 holding.
  • John Overdeck first reported a position in AbCellera Biologics in Q1 2021 and has held it in 22 quarters since.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.